(Press-News.org) Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.1 Further data revealed that, in the case of the TNFα inhibitor infliximab, nearly three-quarters of PsA patients were on doses lower than recommended in international guidelines. 2
In the first study, after 28 weeks of treatment one-third of PsA patients were found to have serum adalimumab trough concentrations below the 5 mg/L level shown to have an optimal effect. However, these low doses still showed reasonable efficacy1
In the second study, low dosing of infliximab in more than 70% of a population of Icelandic and Danish PsA patients did not seem to alter either treatment response or adherence to therapy2
PsA is a chronic inflammatory arthritis associated with psoriasis, which significantly impacts health-related quality of life, and may lead to severe, disabling joint damage.3 Psoriasis occurs in 1-3% of the population,4 with PsA occurring in up to 30% of those of cases.5
One third of PsA patients not receiving optimal dosing of adalimumab
Presenting the results of the Dutch study, lead author Mr. Erik Vogelzang of the Jan van Breemen Research Institute, Reade, Amsterdam, Netherlands reported that serum trough levels of adalimumab of 5- 8 mg/L appeared necessary to achieve the most optimal clinical benefit. Concentrations above 8 mg/L appeared to confer no additional benefit; however, concentrations of approximately 1.0 mg/L showed reasonable efficacy.1
"These results linking serum adalimumab trough concentrations to clinical response in PsA patients confirmed the findings from a previous study in RA patients," 6 said Mr. Erik Vogelzang.
"However, interestingly, of the 103 consecutive patients with PsA prescribed adalimumab, 36 (35%) appeared to be receiving less than optimal dosing, with a trough adalimumab concentration below 5 mg/L (the lowest point of this ideal dose range). A substantial group of PsA patients that use adalimumab are therefore not able to profit from its optimal clinical benefit," Vogelzang concluded.
This was a prospective cohort study in which 103 consecutive patients diagnosed with PsA were treated with 40 mg adalimumab subcutaneously every other week. Adalimumab concentrations at 28 weeks of treatment were measured in serum trough samples, using an enzyme linked immunosorbent assay (ELISA). Clinical response was defined as a change in disease activity score in 28 joints (ΔDAS28) between baseline and week 28. At 28 weeks of treatment, serum trough concentrations ranged from 0.0 to 18.8 mg/L, with a mean of 7.2 mg/L. In 48 (47%), trough adalimumab concentrations exceeded the optimal threshold of 8 mg/L.
Low dosing of infliximab does not appear to alter treatment response or adherence
International guidelines recommend that patients with arthritis PsA prescribed the TNFα inhibitor infliximab should be dosed with 5 mg/kg bodyweight every 8th week. However, responses to lower doses have not been previously well documented.2
Dr Bente Glintborg of the Copenhagen Centre for Arthritis Research, and Centre for Rheumatology and Spine Diseases, Glostrup Hospital, Denmark presented the clinical outcomes in a large cohort of TNFα inhibitor-naïve PsA patients treated with infliximab, stratified by country (Denmark vs. Iceland), and by their dose regimen and escalation.
"More than 70% of Icelandic and Danish PsA patients treated with infliximab received sustained doses below the recommended 5 mg/kg every eight weeks," said Dr Glintborg. "Lower start doses did not appear to affect either drug adherence or response," she added. Thus, in clinical practise a low start infliximab dose with subsequent step up therapy seems to be an efficient strategy.
Danish patients received higher infliximab doses than Icelandic patients at baseline (median (IQR) 3.1 (3.0-3.8) mg/kg vs. 2.3 (2.1-2.9) mg/kg, p END
One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
Low dosing of infliximab does not appear to alter treatment response or adherence
2014-06-11
ELSE PRESS RELEASES FROM THIS DATE:
Romosozumab signif increases bone mineral density and bone content compared with teriparatide
2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.1
Romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular* and cortical† compartments of the spine and hip regions, with important differences ...
Biosimilar CT-P13 matches infliximab in improving ankylosing spondylitis disease activity
2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).1
CT-P13 is the world's first biosimilar monoclonal antibody to receive a positive opinion from an advanced and developed nations' regulatory body. According to Dr Won Park, Inha University Hospital, Korea, and lead investigator ...
New patient empowerment and educational initiatives unveiled at EULAR 2014
2014-06-11
Five different presentations at the European League Against Rheumatism Annual Congress (EULAR 2014) have introduced new patient empowerment and educational initiatives, which are predicted to bring significant benefits to the many thousands of patients worldwide who suffer from a rheumatic disease.
These initiatives include:
A new model of patient care involving self-monitoring and patient initiated follow-up1
An online learning resource to prepare patients and carers to actively engage in research, guideline development, advocacy and media activities2
A new patient ...
EULAR driving research and innovation in rheumatic and RMDs in Europe
2014-06-11
The European League Against Rheumatism (EULAR) has announced today at its Annual Congress major successes in driving the public agenda for addressing the escalating burden of RMDs in Europe. These advances include:
Recognition for Rheumatic and Musculoskeletal Diseases (RMDs) from major European Commission research initiative, Horizon 2020
'FOREUM', Foundation for Research in Rheumatology, grants research funding for four osteoarthritis projects in its first year.
"It is with great satisfaction that we have seen a progressive dedication of EU research funds for RMDs ...
Tendon stimulation the key to repair in 'tennis elbow'
2014-06-11
New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that ultrasound-guided injections of growth factors-containing platelet-rich plasma (PRP) are no more effective in treating recently developed epicondylitis than injections of saline.1
Lead researcher, Patrick Le Goux of the Hôpitaux Universitaires Paris Ile-de-France Ouest, France, commented, "while PRP injections were shown to have no inherent benefit in the treatment of epicondylitis, what is exciting is that pain scores in both treatment groups decreased significantly ...
Higher disease activity scores in obese RA patients
2014-06-11
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that obese patients with rheumatoid arthritis (RA) have higher DAS (disease activity) scores than non-obese patients, irrespective of their disease stage.1 With clinical remission as the ultimate therapeutic goal in RA,2 several studies have demonstrated that treatment to target – a treatment approach guided by its impact on reducing DAS scores – is more effective in lowering disease activity and, ultimately, reaching remission than usual care.3-7 Because obese patients ...
Newly discovered paddle prints show how ancient sea reptiles swam
2014-06-11
Trackways formed on an ancient seabed have shed new light on how nothosaurs, ancient marine reptiles that lived during the age of the dinosaurs, propelled themselves through water. The evidence is described by a team from Bristol and China in Nature Communications today.
During the Mesozoic, 252-66 million years ago, the seas were ruled by a variety of marine reptiles. One of the earliest groups were the nothosaurs, voracious semi-aquatic hunters with elongate bodies and paddle-like limbs. They were the top predators of the Triassic coasts, some 245 million years ago.
Their ...
Forest loss starves fish
2014-06-11
Debris from forests that washes into freshwater lakes supplements the diets of microscopic zooplankton and the fish that feed off them – creating larger and stronger fish, new research shows.
The researchers warn that, as forests are eroded through human activities such as logging, the impacts will be felt in aquatic as well as terrestrial food chains.
In fact, the study was conducted at a Canadian lake chosen because it had suffered ecological disaster during the mid-20th century: acid rain as a result of the local nickel smelting industry.
Despite moves to reduce ...
Sports teams may lose out from having 'too much talent'
2014-06-11
As the FIFA World Cup kicks off and the NBA finals "heat" up, new research suggests that there is such a thing as having too much talent on a sports team. The research indicates that, after a certain point, the addition of more superstar talent to a team can actually be detrimental, resulting in poorer team performance.
The findings are forthcoming in Psychological Science, a journal of the Association for Psychological Science.
The research, led by INSEAD Professor Roderick Swaab, showed that the presence of too many individuals with top talent can undermine players' ...
Nearby satellite galaxies don't fit standard model
2014-06-11
Satellite dwarf galaxies at the edges of the Milky Way and neighboring Andromeda defy the accepted model of galaxy formation, and recent attempts to pigeon-hole them into the model are flawed, an international team of scientists reports.
The mismatch raises questions about the accuracy of the standard model of cosmology, which is the widely accepted paradigm for the origin and evolution of the universe, the astrophysicists say.
A preprint of the research paper, accepted for publication by the Monthly Notices of the Royal Astronomical Society, is online at http://arxiv.org/abs/1406.1799.
The ...
LAST 30 PRESS RELEASES:
Signs identified that precede sudden arrhythmic death syndrome in young people
Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance
Pre-eclampsia is associated with earlier onset and higher incidence of cardiovascular risk factors
Warwick astronomers discover doomed pair of spiralling stars on our cosmic doorstep
Soil conditions significantly increase rainfall in world’s megastorm hotspots
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
Planetary health diet and mediterranean diet associated with similar survival and sustainability benefits
Singapore launches national standard to validate antimicrobial disinfectant products
Molecular stool test could improve detection of tuberculosis in adults with HIV
Suspected fibrocartilaginous embolus in Asian small-clawed otter (Aonyx cinereus)
Enhancing heat transfer using the turbulent flow of viscoelastic fluids
Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue
UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’
New guidelines aim to improve cystic fibrosis screening
Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas
Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition
CCNY physicists uncover electronic interactions mediated via spin waves
Researchers’ 3D-printing formula may transform future of foam
Nurture more important than nature for robotic hand
Drug-delivering aptamers target leukemia stem cells for one-two knockout punch
New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed
New sea grant report helps great lakes fish farmers navigate aquaculture regulations
Strain “trick” improves perovskite solar cells’ efficiency
How GPS helps older drivers stay on the roads
Estrogen and progesterone stimulate the body to make opioids
Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation
Machine learning helps construct an evolutionary timeline of bacteria
Cellular regulator of mRNA vaccine revealed... offering new therapeutic options
Animal behavioral diversity at risk in the face of declining biodiversity
Finding their way: GPS ignites independence in older adult drivers
[Press-News.org] One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumabLow dosing of infliximab does not appear to alter treatment response or adherence